Zoetis Inc. (NYSE:ZTS) Shares Sold by MGO One Seven LLC

MGO One Seven LLC lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 44.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,594 shares of the company’s stock after selling 4,410 shares during the quarter. MGO One Seven LLC’s holdings in Zoetis were worth $970,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Private Wealth Management Group LLC acquired a new position in shares of Zoetis during the 4th quarter valued at about $33,000. Webster Bank N. A. grew its holdings in Zoetis by 89.1% in the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after purchasing an additional 82 shares during the period. Neo Ivy Capital Management acquired a new position in Zoetis during the fourth quarter worth approximately $40,000. LRI Investments LLC purchased a new position in Zoetis during the first quarter worth approximately $43,000. Finally, Ables Iannone Moore & Associates Inc. acquired a new position in shares of Zoetis in the 4th quarter valued at $51,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Stifel Nicolaus restated a “buy” rating and set a $200.00 price objective on shares of Zoetis in a report on Tuesday, August 27th. Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. BTIG Research lifted their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Piper Sandler increased their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $217.11.

Zoetis Stock Up 0.2 %

NYSE ZTS opened at $191.17 on Friday. The stock has a market cap of $87.23 billion, a PE ratio of 36.83, a P/E/G ratio of 2.91 and a beta of 0.88. The business has a 50 day moving average price of $182.85 and a two-hundred day moving average price of $174.50. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The business had revenue of $2.36 billion during the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The business’s revenue was up 8.3% on a year-over-year basis. During the same period last year, the business earned $1.41 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.